A Single-arm, Multicentre, Open Phase Ⅱa Clinical Study of RC48-ADC in the Treatment of HER2 Variant (Mutation, Amplification, Overexpression) Advanced Melanoma
Latest Information Update: 23 Feb 2024
Price :
$35 *
At a glance
- Drugs Disitamab vedotin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors RemeGen
- 18 Feb 2024 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
- 18 Feb 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 28 Nov 2023 Status changed from not yet recruiting to recruiting.